ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and Alphatec (NASDAQ:ATEC – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Risk and Volatility
ClearPoint Neuro has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
Earnings & Valuation
This table compares ClearPoint Neuro and Alphatec”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ClearPoint Neuro | $31.39 million | 11.99 | -$18.91 million | ($0.84) | -15.76 |
| Alphatec | $611.56 million | 3.52 | -$162.12 million | ($1.04) | -13.93 |
ClearPoint Neuro has higher earnings, but lower revenue than Alphatec. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 66.4% of Alphatec shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 22.8% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares ClearPoint Neuro and Alphatec’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ClearPoint Neuro | -67.40% | -114.28% | -48.09% |
| Alphatec | -21.28% | N/A | -19.75% |
Analyst Ratings
This is a summary of current recommendations for ClearPoint Neuro and Alphatec, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ClearPoint Neuro | 1 | 0 | 1 | 0 | 2.00 |
| Alphatec | 1 | 1 | 10 | 0 | 2.75 |
ClearPoint Neuro currently has a consensus target price of $9.00, indicating a potential downside of 32.02%. Alphatec has a consensus target price of $22.82, indicating a potential upside of 57.48%. Given Alphatec’s stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than ClearPoint Neuro.
Summary
Alphatec beats ClearPoint Neuro on 10 of the 13 factors compared between the two stocks.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
About Alphatec
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
